Literature DB >> 11006908

[Hearing screening in newborn infants. Comparative studies and cost analysis with different instruments].

M Heinemann1, A Bohnert.   

Abstract

BACKGROUND: The necessity of screening examinations in newborns today cannot be denied. Up to now, it has only been achieved in a few countries to introduce a general hearing screening for newborns.
METHODS: We examined 100 newborns (200 ears) at their third day of life. All ears were evaluated with the TEOAE-screening-device ECHOSCREEN. In addition, we carried out BERA screening examinations with the ALGO PORTABLE or with the EVOFLASH on 100 of these 200 ears. As a reference method, we utilized TEOAE-examinations with the ILO-88 for all ears.
RESULTS: 4.5% of the 200 ears examined with the ECHOSCREEN were conspicuous due to accumulation of earwax problems. With the ALGO-system, none of the ears was conspicuous. Among the 100 ears examined with the EVOFLASH we found negative results with seven ears (4 children). These findings will be discussed in detail. Furthermore, we analyzed the costs for one-step- and two-step-screenings. Costs for a one-step-screening of both ears would be DM 14.27 with Echoscreen, DM 44.69 with ALGO, DM 32.19 with Evoflash for one patient including material and personnel costs. Costs for a two-step-screening would be DM 16.28 with Echoscreen and ALGO, DM 15.72 with Echoscreen and Evoflash, calculated per child on the basis of 812,173 newborn children in the year 1997 in Germany.
CONCLUSION: On the basis of all these results, we recommend a two-step-screening with TEOAE and BERA-devices.

Entities:  

Mesh:

Year:  2000        PMID: 11006908     DOI: 10.1055/s-2000-5911

Source DB:  PubMed          Journal:  Laryngorhinootologie        ISSN: 0935-8943            Impact factor:   1.057


  9 in total

1.  [Automated hearing threshold estimation in newborns using extrapolated DPOAE input/output functions].

Authors:  T Janssen; A Klein; D D Gehr
Journal:  HNO       Date:  2003-06-17       Impact factor: 1.284

2.  Interdisciplinary approach to design, performance, and quality management in a multicenter newborn hearing screening project. Discussion of the results of newborn hearing screening in Hamburg (part II).

Authors:  Anna-Katharina Rohlfs; Thomas Wiesner; Holger Drews; Frank Müller; Achim Breitfuss; Regina Schiller; Markus Hess
Journal:  Eur J Pediatr       Date:  2010-06-11       Impact factor: 3.183

3.  [Two-tier screening process (TEOAE/AABR) reduces recall rates in newborn hearing screening].

Authors:  T Helge; E Werle; M Barnick; C Wegner; B Rühe; G Aust; R Rossi
Journal:  HNO       Date:  2005-07       Impact factor: 1.284

Review 4.  [Universal hearing screening in newborns. Recommendations for organizing and conducting universal hearing screening for congenital hearing loss in Germany].

Authors: 
Journal:  HNO       Date:  2004-11       Impact factor: 1.284

5.  [Cost analysis of a universal newborn hearing screening for clinics using the State of Hesse as an example].

Authors:  P Böttcher; M Gramss; H A Euler; K Neumann
Journal:  HNO       Date:  2009-01       Impact factor: 1.284

Review 6.  The cost-effectiveness of universal newborn screening for bilateral permanent congenital hearing impairment: systematic review.

Authors:  Stephen Colgan; Lisa Gold; Karen Wirth; Teresa Ching; Zeffie Poulakis; Field Rickards; Melissa Wake
Journal:  Acad Pediatr       Date:  2012 May-Jun       Impact factor: 3.107

7.  Early detection of hearing loss.

Authors:  Götz Schade
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2010-10-07

8.  Economic evaluation of newborn hearing screening: modelling costs and outcomes.

Authors:  Franz Hessel; Eva Grill; Petra Schnell-Inderst; Uwe Siebert; Silke Kunze; Andreas Nickisch; Hubertus von Voss; Jürgen Wasem
Journal:  Ger Med Sci       Date:  2003-12-15

9.  Specific guidelines for assessing and improving the methodological quality of economic evaluations of newborn screening.

Authors:  Astrid Langer; Rolf Holle; Jürgen John
Journal:  BMC Health Serv Res       Date:  2012-09-04       Impact factor: 2.655

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.